AvenCell Therapeutics Inc: Valuation, Funding & Investors
AvenCell Therapeutics Inc is a clinical-stage cell therapy company specializing in the development of both autologous and allogeneic switchable CAR-T cell therapies. The company is focused on utilizing its proprietary Universal Switchable CAR-T cell therapy platform to treat a wide range of hematologic malignancies and autoimmune diseases.
Leadership & Board
- Current Number of Employees
- 59
- Current LinkedIn Followers
- 4,449
Latest Estimated Valuation
- Total Amount Raised
- $112M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $112M
- Latest Funding Round
- Series B
Company Momentum
PositiveAvenCell Therapeutics Inc LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
AvenCell Therapeutics Inc had 59 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
AvenCell Therapeutics Inc had 4,449 followers as of November 9, 2026. The number of followers increased by 15 (0.34%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series B | $112.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Novo Holdings | Series B |
| F-Prime Capital | Series B |
| Eight Roads Ventures Japan | Series B |
| Piper Heartland Healthcare Capital | Series B |
| NYBC Ventures | Series B |
| Blackstone Life Sciences | Series B |
Similar Companies
A snapshot of private companies similar to AvenCell Therapeutics Inc, helping you discover and navigate related company profiles.
